Pratteln, Switzerland, March 29, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc (US: private) announce the initiation of a rolling new drug application (NDA) submission to the U.S. Food and Drug Administration (FDA)…Original Article
Santhera and ReveraGen Start Rolling NDA Submission to the FDA for Vamorolone for the Treatment of Duchenne Muscular Dystrophy
